TET2 and DNMT3A mutations were first described in myeloid neoplasms, such as acute myeloid leukemia (AML), myelodysplastic syndrome or chronic myelomonocytic leukemia (CMML), with CMML carrying the highest frequency of TET2 mutations88. Here, DNMT3A is linked to acute myeloid leukemia.